NeoGenomics NEO Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$99.21M+8.2% | -$108.03M+4.8% | -$113.47M-9.1% | -$104.04M-34.1% | -$77.59M+1.4% | ||
| $35.49M-1.6% | $36.07M-2.9% | $37.14M-2.2% | $37.96M-1.6% | $38.56M-1.4% | ||
| $40.2M-2.7% | $41.32M-0.7% | $41.6M+32.9% | $31.3M+12.1% | $27.92M+11.9% | ||
| —— | —— | —— | $3.33M+18.4% | $2.82M-8.3% | ||
| $13.69M+122% | $6.18M+213% | $1.97M-55.7% | $4.45M-62.3% | $11.82M-41.5% | ||
| —— | —— | —— | $10.68M+11.7% | $9.56M+254% | ||
| -$5.12M-9.1% | -$4.69M-117% | -$2.16M-125% | $8.7M+420% | -$2.72M+32.0% | ||
| —— | —— | —— | —— | —— | ||
| -$3.27M-110% | -$1.56M-121% | $7.28M-12.2% | $8.28M+4.1% | $7.96M+16.5% | ||
| -$693K-115% | -$323K— | —— | —— | —— | ||
| $31.02M-2.3% | $31.75M-2.2% | $32.48M-2.2% | $33.21M-0.7% | $33.45M0.0% | ||
| —— | —— | —— | —— | -$5.66M+5.7% | ||
| $22.42M+329% | $5.23M-61.8% | $13.69M— | —— | —— | ||
| $27.51M+1.9% | $27.01M-12.1% | $30.74M-7.5% | $33.22M-16.9% | $39.98M-2.6% | ||
| $12M-40.2% | $20.06M-23.4% | $26.19M+7.0% | $24.48M-41.5% | $41.87M-22.3% | ||
| -$20.9M-69.4% | -$12.34M— | —— | —— | —— | ||
| -$325K-134% | $962K-21.0% | $1.22M-25.3% | $1.63M-65.9% | $4.78M+2.9% | ||
| —— | —— | —— | -$199.62M-4,277% | $4.78M+2.9% | ||
| -$209.45M+3.4% | -$216.79M-4.6% | -$207.27M-3.4% | -$200.36M-1,503% | $14.28M-41.8% | ||
| $2.12M+25.4% | $1.69M-50.0% | $3.38M-0.5% | $3.4M-0.1% | $3.4M-11.2% | ||
| $515K0.0% | $515K— | —— | —— | —— | ||
| $31.02M-2.3% | $31.75M-2.2% | $32.48M-2.2% | $33.21M-0.7% | $33.45M0.0% | ||
| $35.49M-1.6% | $36.07M-2.9% | $37.14M-2.2% | $37.96M-1.6% | $38.56M-1.4% | ||
| -$5.12M-9.1% | -$4.69M-117% | -$2.16M-125% | $8.7M+420% | -$2.72M+32.0% | ||
| —— | —— | —— | $3.33M+18.4% | $2.82M-8.3% | ||
| —— | —— | —— | —— | -$5.66M+5.7% | ||
| -$3.27M-110% | -$1.56M-121% | $7.28M-12.2% | $8.28M+4.1% | $7.96M+16.5% | ||
| —— | $500K+33.3% | $375K+50.0% | $250K+100% | $125K— | ||
| $12M-40.2% | $20.06M-23.4% | $26.19M+7.0% | $24.48M-41.5% | $41.87M-22.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | $30K+215% | -$26K+68.3% | -$82K+40.6% | -$138K+28.9% | ||
| —— | —— | —— | —— | -$5.66M+5.7% | ||
| $6.89M+2.0% | $6.75M-2.8% | $6.94M-7.3% | $7.49M-7.7% | $8.11M-9.2% | ||
| —— | $2.07M+33.3% | $1.55M+50.0% | $1.03M+100% | $516.5K— | ||
| —— | $6.4M+29.2% | $4.95M+41.2% | $3.51M+70.1% | $2.06M+234% | ||
| $515K0.0% | $515K— | —— | —— | —— | ||
| —— | —— | —— | —— | -$33.18M+4.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does NeoGenomics generate?
- NeoGenomics (NEO) generated $22.4M in operating cash flow over the trailing twelve months.
- What is NeoGenomics's free cash flow?
- After $27.5M of capital expenditures, NeoGenomics's free cash flow was -$51.3M over the trailing twelve months, down 19.8% year over year.
- Where does NeoGenomics's cash flow data come from?
- Every line is extracted from NeoGenomics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
